These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1672872)

  • 41. c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
    Lovekin C; Ellis IO; Locker A; Robertson JF; Bell J; Nicholson R; Gullick WJ; Elston CW; Blamey RW
    Br J Cancer; 1991 Mar; 63(3):439-43. PubMed ID: 1672254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade.
    Tsuda H; Fukutomi T; Hirohashi S
    Clin Cancer Res; 1995 Mar; 1(3):261-7. PubMed ID: 9815981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Breast cancer in the catchment area of the Graz Institute of Pathology. Evaluation of morphologic parameters based on 1,510 cases].
    Hauser H; Beham A; Steindorfer P; Smola MG; Fruhwirth H; Klimpfinger M
    Wien Klin Wochenschr; 1992; 104(23):717-20. PubMed ID: 1335634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast carcinoma in women 35 years and younger: a pathological study.
    Fernandopulle SM; Cher-Siangang P; Tan PH
    Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
    Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
    Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. C-erbB-2 protein and neuroendocrine expression in breast carcinomas.
    Nesland JM; Ottestad L; Heikilla R; Holm R; Tveit K; Børresen AL
    Anticancer Res; 1991; 11(1):161-7. PubMed ID: 1673329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis.
    Lee AH; Dublin EA; Bobrow LG; Poulsom R
    J Pathol; 1998 Aug; 185(4):394-401. PubMed ID: 9828838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
    Lilleng R; Hagmar BM; Nesland JM
    Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
    Gamallo C; Palacios J; Suarez A; Pizarro A; Navarro P; Quintanilla M; Cano A
    Am J Pathol; 1993 Apr; 142(4):987-93. PubMed ID: 7682767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.
    Arnaout AH; Dawson PM; Soomro S; Taylor P; Theodorou NA; Feldmann M; Fendly BM; Shepard HM; Shousha S
    J Clin Pathol; 1992 Aug; 45(8):726-7. PubMed ID: 1357006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
    Barnes DM; Lammie GA; Millis RR; Gullick WL; Allen DS; Altman DG
    Br J Cancer; 1988 Oct; 58(4):448-52. PubMed ID: 2849974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of Her-2/neu oncogene in relation to prognosis of human breast cancer].
    Chen RS
    Zhonghua Bing Li Xue Za Zhi; 1993 Oct; 22(5):291-3. PubMed ID: 7909501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low, intermediate and high grade breast carcinomas as determined by histotyping, immunohistochemical prognosticators and histological grading.
    Martinazzi M; Crivelli F; Zampatti C; Pisani P
    Pathologica; 1992; 84(1089):33-47. PubMed ID: 1323096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.
    Dykins R; Corbett IP; Henry JA; Wright C; Yuan J; Hennessy C; Lennard TJ; Angus B; Horne CH
    J Pathol; 1991 Feb; 163(2):105-10. PubMed ID: 1673154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.
    Schroeter CA; De Potter CR; Rathsmann K; Willighagen RG; Greep JC
    Br J Cancer; 1992 Oct; 66(4):728-34. PubMed ID: 1358163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue.
    McCann A; Johnston PA; Dervan PA; Gullick WJ; Carney DN
    Ir J Med Sci; 1989 Jun; 158(6):137-40. PubMed ID: 2570047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.